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ABSTRACT
Major depressive disorder and the use of antidepressant drugs have both been assoeiated 
with impairments in eognitive and psychomotor performance. Many factors affect 
prescribing decisions, for example efficacy, tolerability, the presence of eo-morbid 
conditions and cost. The present review suggests that the potential of each 
antidepressant to further disrupt eognitive and psyehomotor function in depressed 
patients should also be considered.
An extensive review of the literature identified 64 studies of antidepressants in which 
eognitive and psyehomotor function were assessed with objective psychometric tests in 
healthy volunteers. A database was compiled and results from double-blind, plaeebo- 
eontrolled, crossover studies were combined and analysed to determine the frequency 
and extent of impairments produced by as many antidepressants as possible on a battery 
of psychometric tests.
Where statistically significant evidence of impairment was observed, this was recorded 
and used to calculate an impairment ratio for each antidepressant, which was 
subsequently compared with the impairment ratio obtained for all other antidepressants 
included in the review. Cohen’s d effect size estimates were also calculated in order to 
give an indication of the magnitude of impairments.
The heterogeneity of the drugs and methods of measurement involved in this review 
have highlighted the limitations of the meta-analytie method used, and contrary to 
expectation has not allowed firm conclusions to be drawn.
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ABBREVIATIONS
b.i.d twice daily dose
BNF British National Formulary
CRT eognitive behavioural therapy
CFF critical flicker fusion
DSST digit symbol substitution task
DSM-IV-R Diagnostic and Statistical Manual of Mental Disorders
ES effect size
MAGI monoamine oxidase inhibitor
NERI noradrenaline reuptake inhibitor
PIR proportional impairment ratio
RIMA reversible inhibitor of monoamine oxidase
SD standard deviation
SEM standard error of the mean
SNRI serotonin and noradrenaline reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
TCA trieyclie antidepressant
t.i.d three times daily dose
WHO World Health Organisation
5-HT serotonin
ECT eleetroeonvulsive therapy
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1. DEPRESSION AND PSYCHOPHARMACOLOGY RESEARCH
1.1 Depression
1.1.1 Description
Clinical depression, otherwise known as unipolar depression or major depressive 
disorder, is a Diagnostic and statistical manual o f  mental disorders ed., text 
revision) (DSM-IV-TR; American Psychiatric Association, 2000) axis 1 mood disorder 
characterized by severe sadness, despondency, and a loss of interest or pleasure in 
activities that would normally be considered enjoyable. The features of depression can 
be broadly categorized into four areas: affect, cognition, behaviour and physical
symptoms. Depressed mood and irritability are common affective symptoms, however 
these are not always present and many depressed patients instead report a ‘numb’, 
apathetic feeling; a loss of interest or pleasure in life. This can apply to social and 
recreational activities, personal relationships, and work. In addition to these affective 
symptoms, depression is also assoeiated with dysfunctional cognition, in particular a 
tendency to negative, often irrational or exaggerated, thinking. Thoughts of guilt, 
incompetence, worthlessness, helplessness and hopelessness are common. These 
negative thoughts and feelings can exacerbate the depression (e.g. Verplanken et al., 
2007). Cognitive function can also be disrupted in terms of impaired concentration, 
decision-making and memory. Behaviourally, depressed patients are severely de­
motivated and typically cease to engage in regular activities. It may be difficult to get 
out of bed each morning, attendance at school or work is likely to be poor, and social 
situations or the company of friends and family may be avoided. Other behavioural 
problems that may be observed are psyehomotor retardation (e.g. slowing of speech and 
movement) and agitation (e.g. restlessness, fidgeting). Physical symptoms are also
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frequently reported by depressed patients, and these include sleep disturbances, changes 
in appetite often accompanied by sudden weight loss or gain, and lethargy.
1.1.2 Diagnosis
The DSM-IV-TR identifies three depressive mood disorders: major depressive disorder, 
dysthymic disorder and depressive disorder not otherwise specified. Dysthymic disorder 
is characterized by milder, but ehronie (present for at least two years) symptoms 
compared with major depressive disorder. Depressive disorders not otherwise specified 
include eases where depressive symptoms are present but do not meet the criteria for 
major depressive disorder or dysthymic disorder; for example minor depressive 
disorder, and recurrent brief depression.
Depression appears to be a heterogeneous disorder. Not only do the manifest symptoms, 
severity, and time course vary between individuals but there also appear to be specific 
(if not formally recognized) ‘subtypes’ of depression. Some eases of depression appear 
to be more ‘biological’ in presentation or origin (endogenous depression, which occurs 
apparently without any known environmental trigger), while others appear to be more 
‘psychological’ (reactive depression, thought to emerge in response to environmental or 
personality factors).
This heterogeneity is reflected not least in the DSM-IV-TR criteria. DSM-IV-TR 
criteria for major depressive disorder specify that a patient must have at least five of 
nine possible symptoms present for a minimum of two weeks, and that these symptoms 
must cause elinieally significant distress or impairment in social, occupational or other 
important areas of functioning. The nine symptoms are: depressed mood (most of the 
day every day); diminished interest or pleasure in activities (anhedonia); significant
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weight loss or, less commonly, weight gain; insomnia or hypersomnia; psyehomotor 
agitation or retardation; fatigue; feelings of worthlessness and inappropriate, possibly 
delusional, guilt; impaired concentration and decision making; recurrent thoughts of 
death, suicide ideation or a suicide attempt. Of these symptoms, either depressed mood 
or anhedonia must be present in order to make a diagnosis. In addition, the symptoms 
should not be attributable to substance abuse, a general medical condition or 
bereavement.
1.1.3 Prevalence
Depression is an extremely common disorder. The 2001 WHO annual report estimates 
that 5.8% of men and 9.5% of women will experience a depressive episode within any 
12 month period, and Paykel et al. (2005) suggest that at any one time 5% of the 
European population will be elinieally depressed. Based on the results of an 
epidemiological cohort study Angst (1999) estimates a lifetime prevalence of depression 
in Europe of 17%. Given this high prevalence it is not surprising that the economic 
burden imposed by depression is also high, accounting for 10.3% of all healthcare costs 
in patients aged 15-45 years (Andreasen & Black, 2000).
First onset of depression can occur at any age, including during childhood. A large 
number of patients experience their first episode before the age of 30, although for 
women in particular the first episode is likely to be during adolescence or late teens 
(Burke et al., 1990). There also appears to be a marked gender difference in rates of 
depression, with women worldwide approximately twice as likely to experience 
depression as men (Hammen, 1998).
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Some variability in rates of depression related to soeioeconomie status, marital status, 
educational level and culture has been suggested. The evidence is, however, rather 
mixed. For example, lower soeioeconomie status is thought to be assoeiated with 
higher rates of depression (e.g. Lorant et al., 2007). However, the direction of causality 
is unclear - it could be that depressed individuals are less able to function at work and 
therefore the depression leads to lower soeioeconomie status rather than low 
soeioeconomie status being a risk factor for depression.
The typical duration of an episode of depression can vary, although it is estimated that 
the majority last for between 4 - 6  months. For example, in a ten-year follow-up study 
Coryell et al. (1994) found that 55% of patients had recovered within 6 months. Despite 
this, for many patients depression is a recurrent or ehronie condition. Relapse is defined 
as a worsening of symptoms occurring 2 months or less into recovery, recurrence is a 
new episode occurring more than 2 months after recovery, and ehronie depression is a 
continuous and persistent episode that may vary in severity or intensity but from which 
the individual does not completely recover. It is estimated that as many as 50 -  85% of 
cases of depression in treatment seeking patients are followed by at least one recurrence 
(Keller, 1985), and that chronic depression occurs in 25% of eases (Bennett, 2006). A 
higher number of previous episodes of depression, ‘double depression’ (where major 
depression is eo-morbid with dsythymie disorder), other previous psychiatric disorders, 
and possibly certain demographic factors such as gender and onset during adolescence 
(Lewinsohn et al., 1994) all predict relapse. Similarly, some of the factors that may 
predict ehronie or persistent depression include duration of previous episodes (Keller et 
al., 1986), high stress levels and low social support (e.g. Billings & Moos, 1985), and 
demographic factors such as gender, marital status and level of education (Sargeant et 
al., 1990).
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1.1.4 Co-morbidity
Depression is often aeeompanied by other disorders. Blazer et al. (1994) reported results 
from a US national eo-morbidity survey that showed 56% of all eommunity residents 
with current major depressive disorder also had at least one other diagnosis. A wide 
variety of physical and mental disorders are commonly eo-morbid with depression. For 
example, coronary heart disease (Parissis et al., 2007), conditions involving ehronie 
pain, substance and alcohol abuse (Angst, 1995), eating disorders, and personality 
disorders. Depression and anxiety disorders are also commonly eo-morbid (indeed, 
there is some considerable overlap in their presentation and treatment), for example 
Barlow (1988) reported that 39% of agoraphobia patients, 35% of panic disorder 
patients and 17% of generalized anxiety disorder patients also have concurrent major 
depression or dysthymia. Angst (1995) reported eo-morbidity of depression with panic 
disorder, generalized anxiety disorder, agoraphobia, social phobia and obsessive- 
compulsive disorder with estimates ranging from 6 -  25%.
When depression presents as a eo-morbid disorder it is sometimes difficult to determine 
the cause and effect relationship between the conditions, and whether depression is the 
primary or secondary diagnosis. Either way, eo-morbidity usually implies greater 
impairments in functioning and a worse prognosis/more severe course.
1.1.5 Etiology
The causes of depression vary depending upon which school of thinking one subscribes 
to. The choice of model has obvious implications in terms of predicting the outcome of 
depression and selecting an appropriate treatment. In practice it is probably useful to 
consider a mixture of the following approaches, as the integrated ‘biopsyehosoeial
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model’ attempts to do. This posits that social and psychological aspects of the 
environment trigger biological mechanisms of depression, while intrinsic ‘risk factors’ 
determine the degree of stress which can be tolerated before the trigger is activated.
1,1,5.1 Biological explanations
The exact biological basis of depression remains unknown, however the monoamine 
hypothesis has been the leading biochemical theory for many years. Essentially, it 
proposes that depression is due to a deficiency in one or more of the monoamine 
neurotransmitters: serotonin, noradrenaline or dopamine. Normal function in a 
monoaminergie neuron involves normal rate of release of the relevant neurotransmitter, 
along with normal regulatory actions of the neuron i.e. the enzyme monoamine oxidase 
(responsible for degrading the neurotransmitter), the reuptake pump which removes the 
neurotransmitter from the synapse, and the postsynaptie receptors which react to the 
release of the neurotransmitter. A neurotransmitter defieieney will cause abnormal 
upregulation (i.e. an increase) of presynaptie autoreceptors and postsynaptie receptors. 
The presynaptie autoreeeptors regulate neurotransmitter release, so the consequence of 
upregulation is that neurotransmitter will be detected and the receptor will inhibit 
further release (to avoid excess neurotransmitter) -  further compounding the 
neurotransmitter defieieney. This idea is supported by the mechanism of action of 
different antidepressant drugs; monoamine oxidase inhibitors (MAOIs), for example, 
block the enzyme monoamine oxidase from destroying the neurotransmitter and 
allowing them to accumulate, thus returning the neuron to its normal state and relieving 
depression. The trieyclie antidepressants (TCAs) block the re-uptake pump, again 
allowing the neurotransmitter to accumulate, and relieving depression. However, this 
theory of disturbed brain biochemistry is gradually being challenged, with many arguing 
it is too simplistic. The fact that antidepressant drugs increase neurotransmitters almost
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immediately, but it typically takes several weeks (e.g. Anderson et al., 2000) for an 
improvement to be observed supports this idea. Researchers are increasingly looking 
towards interactions between the serotonin and noradrenaline systems, and the effect of 
these on activity in other brain areas to explain depression (e.g. Heninger et al., 1996; 
Brunello et al., 2002).
LL5.2 Cognitive explanations 
The classic cognitive-behavioural explanation of depression is Seligman’s (1975) 
learned helplessness theory. The basic tenet is that depression stems from a lack of 
control over one’s environment. Once lack of control has been leamt, the individual 
becomes hopeless - passive in the face of stressors, believing that they cannot influence 
events, and expectant of negative outcomes. The theory was later adapted (Abramson et 
al., 1978) to suggest that hopelessness, and therefore depression, is the result of a 
negative attributional style. More speeifieally, a depressed individual will tend to view 
negative events as having internal, stable and global causes, and positive events as 
having external, unstable and specific causes. In a student sample Abramson et al. 
(2002) showed that those who were initially classified as having a negative attributional 
style were seven times more likely to be clinically depressed when they were followed 
up 2 years later. While negative attributions do appear to be a feature of depression 
causality cannot be inferred from this.
An alternative to Seligman’s theory is Beck’s (1997) self-schema model. This model 
proposes that a negative schema of automatic and dysfunctional thoughts are developed 
during early life, which later systematically influence thoughts about the self, others and 
external events. These ‘errors of thinking’ include overgeneralisation (drawing 
conclusions based on one negative event, and applying it to other, unrelated situations).
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selective abstraction (inappropriately focusing on one small detail which is perceived to 
be negative), and personalization (inappropriately interpreting events as a personal 
affront). When a stressful event is encountered the negative schema is activated, 
leading to distorted thoughts or interpretations of the event that can cause depression. 
Once again, determining cause and effect is very difficult - depressed mood and 
negative thinking share a two-way relationship; negative thinking can lower mood, and 
depressed mood can encourage negative thinking.
L 1.5.3 Social explanations 
Prevalanee of depression can be high among certain groups of people, e.g. those with 
low income, ethnic minorities or those lacking social support networks (Jenkins et al., 
1998), suggesting that these may constitute risk factors for depression. The assumption 
here is that these factors may be associated with lower quality of life, greater exposure 
to acute stressors, and fewer resources available to deal with related problems. Again, 
these findings should be interpreted with caution as increased risk does not necessarily 
imply causality.
1.1.6 Treatments
The treatment chosen will largely be informed by the model of etiology adopted. Within 
the framework of the psyehobiological model a combination of drug treatment and 
psychological intervention would represent the ideal.
L 1.6,1 Antidepressant drugs 
Since the discovery of the monoamine oxidase inhibitors (MAOIs) and the tricyclic
antidepressants (TCAs) in the 1950s, a number of different antidepressant drugs have
become available for the treatment of unipolar major depression. While the TCAs are
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still commonly prescribed, since the 1980s these have been joined by the selective 
serotonin reuptake inhibitors (SSRIs) and reversible inhibitors of monoamine oxidase 
(RIMAs), and more recently newer compounds such as serotonin and noradrenaline 
reuptake inhibitors (SNRIs), noradrenaline reuptake inhibitors (NERIs) and other 
atypical compounds. The National Institute for Health and Clinical Excellence (NICE; 
2004) recommend antidepressants, and particularly SSRIs, as first line treatment for 
depression.
1.1.6.1.1 Monoamine oxidase inhibitors (MAOIs)
The MAOIs include phenelzine, tranylcypromine and isocarboxazid. They exert their 
antidepressant effect by blocking degradation of serotonin, dopamine and noradrenaline 
by monoamine oxidase. This increases the available neurotransmitter by allowing 
accumulation in the neuron, thus enhancing release and effects at postsynaptie 
receptors. Antidepressant action may take several weeks to become apparent. MAOIs 
are no longer recommended due to dangerous interactions with foods containing 
tyramine (MAOIs suppress the metabolism of tyramine which causes a large release of 
noradrenaline, which in turn can result in hypertensive crisis, cardiac arrhythmia, 
hyperthermia and cerebral hemorrhage). Side effects of MAOIs include dry mouth, 
blurred vision, urinary retention, sleep disturbance, orthostatic hypotension, and sexual 
dysfunction.
1.1.6.1.2 Reversible inhibitors o f monoamine oxidase (RIMAs)
The RIMA antidepressants include drugs such as moelobemide and brofaromine. They 
are a newer class than the MAOIs but they also exert their antidepressant action by 
inhibiting monoamine oxidase. Unlike MAOIs the effects of RIMAs are selective and 
reversible and as a result are not associated with the interactions and serious side effects
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which proved to be problematic with the MAOIs. A meta-analysis conducted by Lotufo- 
Neto et al. (1999) suggests that the RIMAs have comparable efficacy and tolerability to 
the trieyclie antidepressants and selective serotonin reuptake inhibitors.
1.1.6.13 Tricyclic antidepressants (TCAs)
Imipramine was the first TCA, others include clomipramine, amitriptyline, nortriptyline, 
protriptyline, maprotiline, and doxepin. TCAs exert their antidepressant effect by 
blocking serotonin and noradrenaline reuptake into presynaptie neurons. This increases 
the available neurotransmitter in the synapse. In addition to this therapeutic effect, the 
TCAs also block other postsynaptie receptors (cholinergic muscarinic receptors, ai 
adrenoceptors and histamine Hi receptors). This non-specific pharmacological action 
has been found to result in adverse behavioural and eognitive effects (Beaumont et al., 
1996; Peretti et al., 2000) and in a range of somatic adverse events including orthostatic 
hypotension, cardiac arrhythmias and tachycardia, convulsions, dry mouth, tremor and 
blurred vision. One serious side effect caused by blocking histamine Hi receptors is 
sedation. This particular effect is sometimes used therapeutically. Elderly depressed 
patients, for example, may be administered a TCA as a noete dose in order to improve 
sleep quality. However in an ambulant outpatient population, particularly an elderly 
one, it is crucial that any improvement in sleep quality is not outweighed by sedation 
which lasts into the daytime, bringing with it the risk of accident and/or injury and falls 
(Thase, 2006; Liu et al., 1998). TCAs are not suitable for patients who cannot tolerate 
the side effects (compliance is likely to be low in these eases), or suicidal patients 
(TCAs are fatal in overdose).
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1.1.6.1.4 Selective serotonin reuptake inhibitors (SSRIs)
After the discovery and development of the TCAs, the next major advance in 
antidepressant drug treatment was the SSRIs. They are now the most widely prescribed 
antidepressant. The five most popular SSRIs are fluoxetine, sertraline, paroxetine, 
fluvoxamine and citlalopram. SSRIs act by blocking the serotonin reuptake pump, 
leading to an increase in serotonin. This increase in serotonin leads to down regulation 
of autoreeeptors, which in turn increases release of serotonin (Stahl, 1999).
Although the TCAs appear to be as effective as the SSRIs in the treatment of depression 
(Peretti et al. 2000; Pinder, 2001; Hindmareh, 2001) and both classes of drug have a 
similar onset of action, the use of SSRIs is more generally favoured because of their 
superior tolerability profile (Snow et al., 2000; Anderson, 2001). As their name 
suggests, because the SSRIs are selective for serotonin receptors they do not produce 
the anticholinergic (dry mouth, blurred vision, constipation etc) or cardiovascular side 
effects seen with TCAs. This is not to say the SSRIs are completely devoid of unwanted 
effects. The serotonin receptors implicated in depression are thought to be 5-HTi, 
however the SSRIs do not act specifically at 5-HTi receptors, and therefore also cause 
stimulation at 5 -HT2 and 5 -HT3 receptors that can lead to unwanted side effects 
including agitation, akathesia (restlessness aeeompanied by excessive, usually 
repetitive, movements such as foot tapping or pacing), anxiety, insomnia, sexual 
dysfunction, nausea, diarrhoea and headache. In addition the SSRIs are assoeiated with 
a specific withdrawal syndrome (Haddad, 1998), and withdrawal should be gradual in 
order to avoid this. This said, the improved side effect profile of SSRIs over TCAs 
means that they are suitable for long term use, a move which has increasingly been 
assoeiated with better outcomes. SSRIs are possibly not as effective as the TCAs (or 
SNRIs) in severe depression (Anderson & Tomenson, 1994), although the SSRIs also
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have the advantage of being less toxie in overdose (Peretti et al., 2000). This highlights 
the importance of tailoring the drug treatment to the needs of the individual patient.
1.1.6.1.5 Other antidepressants
The serotonin and noradrenaline reuptake inhibitors (SNRIs e.g. venlafaxine) and 
noradrenaline reuptake inhibitors (NERIs e.g. reboxetine) are more recently developed 
reuptake inhibiting drugs selective for specific neurotransmitters/combinations of 
neurotransmitters. The aim with these drugs is to increase or maintain efficacy while 
reducing the potential for unwanted side effects.
Other ‘atypical’ antidepressants are also available (e.g. mirtazepine, trazodone). The 
mechanisms of action of these drugs are unlike any of the other drug classes described 
above. In addition, their mechanisms ofl;en differ from each other.
1.1.6.1.6 Patient compliance
With all the antidepressant drug treatments mentioned above monitoring side effects is 
very important as they can affect patient compliance, which ultimately affects efficacy. 
In a review of controlled therapeutic studies Anderson & Tomenson (1995) observed a 
dropout rate of up to 33%, and higher rates still are observed in clinical practice 
(Pampallona et al., 2002). Vinberg (2007) emphasises the role of practitioner in 
informing patients of known side effects and encouraging them to report side effects, 
particularly unexpected ones, when prescribing drugs. These should then be 
documented and disseminated, and in the long term should help to prevent serious side 
effects and increase compliance with drug treatments.
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L L 6. L 7 Responsiveness to drug treatment 
It is commonly thought that antidepressants have a delayed onset of action, with several 
weeks of drug treatment necessary before any improvement in depressive symptoms is 
observed (e.g. Anderson et al., 2000). Recent work is beginning to challenge this view. 
For example, in a short review article Mitchell (2006) suggests that the use of 
inappropriate outcome measures has artificially inflated estimates of onset of action. 
Response or remission rates do not reflect first onset of action but a clinically relevant 
change in symptomatology -  presumably initial response occurs much earlier. In 
addition, Mitchell identifies several methodological factors which affect estimates of 
onset of action, not least infrequent assessments of symptom change which are not made 
soon enough after initiation of treatment to allow early response to be captured. 
Similarly, based on the results of a systematic review Taylor et al. (2006) suggest that 
SSRI onset of action can be observed after one week.
In terms of the level of response across patients, not all patients will respond equally to 
antidepressant medication and there is a sub-group of patients who will not respond at 
all. It is estimated that 30-40% of patients do not respond to first line antidepressant 
treatment, and 60-70% of those who do respond do not achieve complete remission 
(Fagiolini & Kupfer, 2003). Kampf-Sherf et al. (2004) note that SSRIs are effective in 
approximately 67% of patients, and that those who respond or do not respond to SSRI 
treatment are characterized by certain biochemical and neuropsychological features (e.g. 
low serotonergic activity; and better performance on simple neuropsychological tasks 
[Rey-Osterreith Complex Figure Task; and Benton Visual Retention Task -  left field 
errors] contrasted with poorer performance on complex neuropsychological tasks 
[WAIS Arithmetic, Block Design and Similarities sub-tests; Hooper Visual 
Organisation Test; and Benton Visual Retention Task - correct responses] in
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responders). This underlines the importance of tailoring the treatment to the individual 
patient.
l .L  6.2 Other treatments 
Other treatments for depression include eognitive or cognitive-behavioral therapies 
(CBT), and eleetroeonvulsive therapy (ECT).
ECT involves the discharge of an eleetrie current through the brain, for less than one 
second, with the aim of inducing an epileptic seizure. This seizure activity is thought to 
be responsible for improvements in mood, although the exact mechanism is unclear. 
ECT is administered as a course of treatments usually given two to three times weekly, 
over the course of several weeks. It is no longer used as a first line therapy in 
depression, although in severe, treatment resistant eases it can be useful in combination 
with drug treatment.
Cognitive behavioural therapy for depression usually involves an initial behavioural 
element intended to increase physical and social activity (for example, setting objectives 
for achieving simple tasks, and planning pleasant activities) and improve energy and 
mood. The eognitive phase follows which involves first educating the patient about the 
interplay between thoughts, behaviour and emotion; and secondly learning and 
rehearsing strategies to identify and challenge negative schemas, and cope with 
situations where these schemas tend to operate. The findings of research comparing the 
effectiveness of CBT with pharmacotherapy has been promising, but mixed, and CBT is 
commonly used in addition to drug treatments for depression.
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1.2 Cognitive and psyehomotor disruptions in depression
Besides the dysfunetional eognitive processes that seem to perpetuate depression (e.g. 
negative thinking) impairments in attention, psyehomotor performance and memory are 
often reported in depressed patients (Widloeher, 1983; Veiel, 1997; Gallassi et al., 
2001). For example, increasing psyehomotor and eognitive retardation have been 
correlated with the degree of depression (Cohen et al., 1982). Other work has identified 
impairments in working memory and verbal recall (e.g. Austin et al., 1999; Brown et al., 
1994), reaction time (e.g. Austin et al., 1999; Kalb et al., 2006), verbal fiueney (e.g. 
Beats et al., 1996; Elliot et al., 1996), and attentional set-shifting tasks (e.g. Beats et al., 
1996; Purcell et al., 1997), among others.
While there has been some variability in findings regarding the aspects of function 
affected, and whether severity or subtype of depression plays a role, most would agree 
that decrements in eognitive performance associated with depression further affect 
quality of life and ability to function occupationally.
1.3 Psvchopharmacology research
1.3.1 Behavioural toxicity
Few drugs are free of side effects, and establishing safety and tolerabilty is a routine 
process. In addition to the physical side effects assoeiated with some antidepressants 
(TCAs with arrhythmias, drowsiness, blurred vision, constipation; and SSRIs with 
gastro-intestinal effects, anxiety, headache, insomnia; for example), these drugs can also 
produce unwanted effects on behaviour and performance. These effects have been 
referred to as ‘behavioural toxicity’ (Hindmareh & Kerr, 1992). This is particularly 
valid as eognitive and behavioural deficits are common symptoms of depressive illness. 
It is therefore important that any impairment in cognitive and psyehomotor performance
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resulting from antidepressant treatment does not exaggerate the symptoms of 
depression, whieh could lead to difficulty establishing an adequate therapeutic dose, 
reduce patient compliance and ultimately delay recovery (Hindmareh, 1997). In 
addition, as antidepressants tend to be prescribed to ambulant outpatients any disruption 
of eognitive function or psyehomotor performance can potentially put the patient at 
increased risk of accident or injury. In an epidemiological study, Alvarez & Carmen Del 
Rio (2002) suggested that as many as 10% of road traffic accident victims were taking 
psychotropic medication whieh may have been a contributing factor, for instance.
The effects of various antidepressant agents upon eognitive function and psyehomotor 
performance have begun to be mapped in clinical studies and reviews (e.g. Hindmareh 
et al., 1992; Kasper & Heiden, 1995; Amado-Boeeara et al., 1995; Volz & Sturm, 1995; 
Thompson, 1991; Dumont et al., 2005; Gorenstein et al., 2006). In depressed patients, it 
is very difficult to separate the effects of depression from the effects of antidepressant 
drugs and it is likely that any decrements in performance are actually due to a 
combination of the two. The use of healthy volunteers in clinical studies of 
antidepressants therefore allows the effects of the drug to be isolated. This information 
can then be applied to prescribing decisions involving patients.
1.3.2 Healthy volunteers vs. patients
The use of healthy volunteers to isolate the effects of antidepressants on performance 
does not imply that studies in depressed patients are unnecessary. For example, it is 
important to evaluate the effects of prolonged use of antidepressants as in clinical use 
they can be administered for months or even years. There is a tendency for the 
maximum length of treatment in healthy volunteer studies, even with repeated dosing, to 
be much shorter than patient studies. Many studies in healthy volunteers measure
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performance after a single dose of drug, a very unrealistic regimen. In patients, after 
several doses tolerance to behavioural toxicity may develop -  this phenomenon would 
not be captured by studies employing an acute dose.
In addition to methodological issues, there are also eharaeteristies of depressed patients 
not present in healthy volunteers that makes extrapolating fi*om one group to the other 
complex. Altered brain neuroehemistry in depressed patients may mean drug response 
differs from that in healthy volunteers, for instance. Also, in patients one may expect to 
see an improvement in cognition as depression lifts.
There are also qualitative differences between the two groups. In healthy volunteers, 
behavioural impairments represent sub-optimal performance and as there is no clinical 
benefit to drug-taking are viewed entirely negatively. In patients however, while drug- 
related impairments may be troublesome, they are likely to be weighed against the 
positive effects brought about by relief from symptoms.
1.3.3 Psychometric measures
The tasks used across studies to measure performance vary widely, from clinical tools 
and neuropsychological tests, to tasks designed to tap specific eognitive or psyehomotor 
ftinetions and analogues of ‘real-life’ performance (e.g. driving simulators). The number 
and nature of tasks used vary according to the subject population, other methodological 
features of the study, and the research group eoneemed.
Many measures are sensitive to changes in performance but not specific; that is, few 
tasks assess only one aspect of eognitive function. Usually, more than one skill or 
domain of performance is involved in performing the task in question. Conversely, one
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task does not neeessarily measure all aspects of a particular facet of performance. As a 
result tests are rarely administered singly, and batteries of tests are used to identify and 
eharaeterize impairments assoeiated with particular drugs. Even so, no one battery is 
exhaustive and so comparing effects across many studies is a very useful exercise.
When interpreting the results of cognitive and psyehomotor tasks one should consider 
the reliability, validity and sensitivity of those tasks. Simply, reliability refers to the 
consistency of a task over time and between individuals (i.e. are the results produced 
replicable?), validity refers to the ability of a task to measure the construct it purports to 
measure (i.e. is the task fit for purpose?) and sensitivity refers to the ability of the task 
to detect change in performance. Sensitivity is often compromised by ceiling effects -  
particularly in young healthy volunteers, the design of the task sometimes allows a 
participant to achieve 100% accuracy. In this situation it is difficult or impossible to 
detect improvements in performance (e.g. where a drug whieh has stimulant action).
Another factor whieh could affect performance on a task is practice, or learning, effects. 
In other words, performance improves over time given repeated exposure to a task. This 
is a particular problem with crossover designs, or where participants are experimentally 
non-naïve. Practice effects are not universal, some tasks are more affected than others 
e.g. DSST (Petursson et al., 1983; De Monte et al., 2005), and the Paced Auditory Serial 
Addition Task (PASAT) and Stroop Task (Beglinger et al., 2005) appear to be practice- 
sensitive performance tasks. Many tasks appear to have a performance plateau, beyond 
whieh improvement after further repetition is not observed. In clinical drug studies, the 
ideal would be to ‘train’ all participants to reach a performance plateau on all tasks 
before drug dosing.
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The points above highlight the importance of choosing tasks wisely, based on the 
population and study design, and also in consultation with the existing literature on the 
expected and previously observed effects of a drug.
1.4 Summary
Given the prevalence of depression and the wide variety of alternative treatments 
available, it is necessary to be able to discriminate between antidepressant drugs. While 
safety and effieaey are obviously paramount, it is also important to consider the 
tolerability of a drug, and the effects it may produce on eognitive and psyehomotor 
performance. The ‘behavioural toxicity’ of a drug has implications in terms of treatment 
compliance and effieaey. In addition, characterising antidepressants based on their 
potential to impair eognitive and psyehomotor performance as well as other features of 
the drug (e.g. side effects, eontra-indieations, cost) could provide invaluable evidence in 
making prescribing decisions tailored to the individual.
The present review aims to investigate the impairment potential of as many 
antidepressants as possible, by combining the results of studies conducted to assess 
antidepressant drug effects on batteries of objective psychometric tests in healthy 
volunteers.
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2. ANTIDEPRESSANTS REVIEW
2.1 Introduction
There is a large body of published research comparing the effects of antidepressants 
with placebo and with other antidepressants, on cognitive and psychomotor function in 
healthy volunteers. Very often these studies aim to demonstrate that a newly developed 
or reformulated drug is equivalent to placebo, or superior to an older drug known to 
impair performance. Some of the findings from these studies appear to be consistent for 
example the impairing effects of amitriptyline are unequivocal, however the effects 
found with other drugs are less clear cut.
Meta-analysis is a mathematical method for combining data from multiple studies. The 
data to be combined should be identified through a process of detailed and systematic 
review. One very common pitfall with meta-analysis is bias in selecting studies to 
include. This can be due to an inadequate search for relevant studies, or can be more 
subtle, for example studies with positive findings are more likely to be published which 
makes these studies more likely to be included. The use of explicit and justified criteria 
for inclusion of data once relevant studies have been identified is crucial, in order to 
avoid bias.
A fiirther difficulty with meta-analysis is heterogeneity of studies. Obviously, as the 
purpose of meta-analysis is to address a specific question the studies selected will be 
similar but it is inevitable that there will be differences in methodology. In clinical 
studies of antidepressant effects in healthy volunteers all of the following vary: age and 
gender of sample; sample sizes; inclusion/exclusion criteria; dose and regimen (acute 
vs. repeated); number and schedule of assessments; washout periods. In addition, study
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designs can be crossover or parallel; some studies include a verum and some do not; and 
statistical analysis can vary (some studies make comparisons with placebo treatment, 
others with baseline performance, for example).
Despite these concerns, a synthesis of the literature concerning antidepressant drug 
effects on cognitive and psychomotor performance would be useful to reconcile 
conflicting results and provide a comparison across as many antidepressants as possible.
The present review will focus on studies of antidepressants in which objective 
assessments of cognitive and psychomotor performance were made. In order to 
maximize similarities in methodology among the studies included in the review the 
following criteria were also set: double blind, placebo-controlled, crossover designs in 
healthy volunteers, which included a positive internal control.
The proportional impairment ratio (PIR) calculation is a technique adapted from that 
used in pharmacovigilance (Stather, 1998). Shamsi & Hindmarch (2000) have described 
the method in a review of antihistamines. The PIR shows whether a particular drug, in 
this case an antidepressant, is associated with cognitive or psychomotor impairments, 
and if so how that impairment compares to the effects of other drugs. The greater the 
PIR the greater the impairments associated with the use of that antidepressant. A PIR 
value of zero indicates that there is little or no evidence of impairment.
Effect size estimates are widely used in meta-analytic work, and measure the magnitude 
of a treatment effect, in this case the magnitude of impairments (or improvements) in 
cognitive and psychomotor performance associated with particular antidepressant drugs.
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Following identification of relevant studies, PIR and effect size analyses will be 
conducted in order to identify which antidepressants are most associated with 
impairments of cognitive and psychomotor fonction, and which fonctions are most 
affected/spared.
2.2 Methods
2.2.1 Literature Search
A literature search using the PubMed and ISI Web of Science (WOS) databases was 
conducted to identify placebo and comparator controlled crossover studies which 
reported the effects of antidepressants on assessments of cognitive and psychomotor 
performance in healthy volunteers, in papers published in the 20 years between January 
1986 and April 2006. Search terms included ‘cognitive fonction’, ‘cognitive’, 
‘cognition’, ‘psychomotor’, ‘psychometric’ ‘objective test’, ‘healthy’, ‘antidepressant’ 
and specific antidepressant drug names. Where a large number of ‘hits’ were returned 
the results were limited using the term ‘NOT patient’, or by combining search terms 
with the AND operator.
The following PubMed limits were set: human subjects, all age groups, years 1986- 
2006, English language documents, all document types, plurals, ReADER. The 
following WOS limits were set: human subjects, all years (1981-2006), English 
language documents, all document types.
All studies were required to make use of antidepressant drugs; these were defined as 
drugs where the only (or main, if more than one) indication was major depressive 
disorder. Drugs for bipolar disorder (e.g. lithium) were not included, and 
herbal/alternative medicines (e.g. St. Johns Wort) were not included.
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Studies employing a parallel design, interaction studies (with alcohol or other CNS 
substances) where there were no ’clean’ conditions, and studies in children, patients and 
recreational drug-users were excluded. Studies where there was no comparator drug, or 
where the comparator drug was not an antidepressant were excluded. All studies 
included were double blind and crossover. Studies involving both acute and repeated 
dosing regimens were included.
All studies included were publications in peer-reviewed journals. Studies published in 
abstract format were not included to prevent duplicate entry of studies published both in 
abstract and full paper formats.
2.2.2 Data Collection & analysis
The present review concentrates only on objective psychometric assessments and does 
not consider measures of efficacy, side effects, or potential interactions with other drugs 
or substances. The results of subjective measures, such as mood rating scales, are not 
considered. A database was constructed to record details of each eligible study, 
including: the drugs used; dose and duration of treatment; number of study periods; 
length of washout period; number, age and gender of participants; test schedule; 
psychometric tests used; and outcomes of psychometric tests.
2.2.2.1 Proportional impairment ratio (PIR)
For each antidepressant drug in every study included in the review results were 
tabulated according to whether there was statistically significant evidence of impairment 
on each test used. If a significant difference (p<0.05) between the test drug and placebo 
(or the comparator and placebo) was observed, indicating impaired cognitive or
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psychomotor performance, then that test score was listed as an ‘impairment’. If no 
statistically significant effect was found, then this was listed as ‘no impairment’. If a 
statistically significant improvement in performance was observed this was initially 
tabulated as an ‘improvement’ and later combined with the ‘no impairment’ category. 
This procedure was followed for each psychometric test in all of the studies reviewed. 
Where there were multiple time points under one drug condition or where more than 
one response measure was reported for a single test, and the observed effects were 
inconsistent this was coded as 0.5 in each of the ‘impairment’ and ‘improvement’ 
categories. The total number of instances of ‘impairments’ and ‘no impairments’ for 
each drug were entered into the PIR analysis.
In order to calculate the PIR for a specific antidepressant the number of impairments 
observed with that particular drug was divided by the sum of the number of impairments 
plus the number of no impairments observed with that particular drug to yield a ratio of 
impairments to no impairments. In order to provide an index of the extent of impairment 
with relation to other antidepressants the sum above was in turn divided by the number 
of impairments observed for all other antidepressants in the review divided by the sum 
of the number of impairments plus the number of no impairments observed with all 
other antidepressants included in the review. See Figure la.
A PIR was also calculated for each of 7 cognitive/psychomotor test functions. The 
classification of tests into categories is described in section 2.2.3. During coding, where 
each test was listed as being impaired or not impaired under each drug condition, as 
described above, that impairment (or non-impairment) was sub-divided into one of 
seven categories, each of which represented a particular cognitive/psychomotor 
function. The PIR for each function was calculated by dividing the number of
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impairments observed with that particular function by the sum of the number of 
impairments plus the number of no impairments observed with that particular function. 
In turn, this was divided by the number of impairments observed for all other functions 
divided by the sum of the number of impairments plus the number of no impairments 
observed with all other functions. See Figure lb.
Following the calculation of PIR values each drug was ranked with respect to its 
potential for disrupting cognitive and psychomotor performance. Similarly, each 
function was ranked with respect to the amount of impairment detected by tests 
indexing that function.
2.2.2,2 Estimates o f  effect size (ES)
In addition to PIRs a Cohen’s d (Cohen, 1977) estimate of ES (the standardized 
difference between two means) was calculated for every significant finding where 
means and standard deviation (SD), or means and standard error of the mean (SEM), 
were available. In most cases, it was only possible to calculate an ES estimate for 
significant findings due to a reporting bias in published studies. Therefore, ES estimates 
were only calculated where an antidepressant significantly impaired or improved 
performance on a particular test. The paired t-test and/or ANOVA F values were not 
used to calculate Cohen’s d estimates due to the correlated design of the review (it was a 
requirement of inclusion that all studies were crossover, and therefore repeated 
measures) in order to avoid artificially inflating the effect size estimates. Where a 
particular test was significantly impaired or improved at multiple time points or across 
multiple response measures of a single test, the Cohen’s d estimates were calculated for 
each time point and then combined into a mean ES.
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Cohen’s d was calculated for each test in each study using the placebo vs. drug mean 
(and SD) scores, as follows:
d =  ( M l - M 2 ) / a
where:
Ml = placebo mean 
M2 = drug mean 
o = pooled SD
a = V(SDl^ + SD2^)
The SDs for placebo and drug means were combined into a pooled SD (square root of 
the sum of the two squared SDs). Contrary to usual convention whereby Ml and M2 are 
determined according to the prediction being made and the expected direction of effect. 
Ml was always the placebo mean and M2 was always the drug mean. This was due to 
the fact that order of assignation of means would depend on the measure in question 
(e.g. where the response measure was correct answers an increase would equate to an 
improvement, whereas if  the response measure was reaction time an increase would 
equate to an impairment) and also the drug in question (i.e. although a verum would be 
expected to lead to a decrement in performance, the direction of effect with other drugs, 
particularly newer ones, may be less predictable). Therefore, as drug associated 
impairment was the main focus of this research, placebo means were always M l and 
drug means always M2. The signs were then adjusted accordingly afterwards, 
dependent upon the response measure in question.
Individual Cohen’s d values were combined to give an overall ES estimate for each 
drug, for each drug class and for each cognitive/psychomotor function.
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2.2.3 Test categories
The psychometric tests used to evaluate cognitive and psychomotor performance were 
grouped into 7 categories, broadly representing the following functions: divided 
attention, sustained attention, working memory, long term memory, executive function, 
motor performance and reaction time.
Each test in each study was assigned to a category based on the function it was thought 
to most closely approximate, recognizing that most tests do not measure only one aspect 
of performance. However, due to the large variety of measures used across studies it 
was desirable to use a classification system as it was impractical to treat each measure 
individually.
2.3 Results and Discussion
A total of 64 relevant studies from 62 published papers were identified and included in 
the review. A summary is presented in Table 1. One study was identified that fitted the 
inclusion criteria but was excluded and is mentioned here as a special case. The study 
was reported in a paper by Hindmarch et al. (1990) and compared the effects of 
sertraline, mianserin and placebo on psychomotor function in healthy elderly volunteers. 
However, it was not possible to add this study to the database owing to the fact that 
results of the statistical analysis were not reported. It is also noteworthy that 10 of 21 
participants dropped out of the study due to adverse events associated with mianserin. 
A forther study (Ogura et al., 1987) was excluded because the drug under investigation, 
sibutramine, although at the time thought to have antidepressant action has since been 
found ineffective as an antidepressant.
Page 32 of 124
Data were available for a total of 31 antidepressants, of which; 8 were selective 
serotonin reuptake inhibitors (SSRIs), 2 were serotonin and noradrenaline reuptake 
inhibitors (SNRIs), 2 were noradrenaline reuptake inhibitors (NERIs), 8 were tricyclic 
or tetracyclic antidepressants (TCAs), 5 were reversible inhibitors of monoamine 
oxidase (RIMAs) and 6 were ‘atypical’ antidepressants. 16 of the 31 drugs included in 
the review are listed in the British National Formulary (BNF; 53"^  ^ ed.). Of the 
remainder, it is worth noting that two drugs, the atypical compound nomifensine and the 
SSRI zimelidine, have been withdrawn from use due to the risk of serious adverse 
effects associated with their use. One of the RIMAs (RS-8359) was an un-named 
compound with antidepressant action.
36 studies employed an acute dosing regimen, while 28 studies employed a repeated 
dosing regimen. While repeated dosing best reflects how a drug might be administered 
in practice, an acute regimen puts the healthy volunteer at the minimum of risk.
2.3.1 Test categories
Each psychometric test used in every study included in the review was assigned to one 
of seven test categories, each representing a particular cognitive or psychomotor 
function, or group of functions. Table 2 presents this categorization. Each test category 
was further divided into subcategories.
Divided attention refers to the ability to perform two tasks simultaneously. Early 
research established that divided attention tasks are more difficult where the two parts 
of the task are very similar, particularly where the tasks require processing in the same 
modality (e.g. Treisman & Davies, 1973; McLeod, 1977), and where the tasks are more 
complex (e.g. Sullivan, 1976). The ability to divide attention between two tasks can be
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improved with practice (e.g. Spelke et al., 1976). Most impairment would therefore be 
expected where the two tasks involved were similar, un-practised, and complex. Only 
two measures of divided attention were identified in the studies reviewed - the Stroop 
colour-word interference task (Stroop, 1935) and also a divided attention task (DAT) 
where the main task was to track a moving object using a joystick while also responding 
to periodically occuring stimuli in the peripheral visual field (Moskowitz, 1973).
Sustained attention, or vigilance, is defined as the ability to attend to a task or stimulus 
for a prolonged period, often under monotonous conditions. Tasks which reflect 
sustained attention require the participant to remain focused on the relevant activity 
without becoming distracted, which would consequently interfere with performance. 12 
types of sustained attention task were identified in the review, and these were grouped 
into three sub-categories -  cancellation tasks, digit symbol substitution (DSST) and 
continuous performance. The cancellation tasks and DSST are typically shorter in 
duration than the continuous performance tasks. Cancellation requires the participant to 
remain focused long enough to complete the task accurately (usually ‘crossing out’ 
target items from a sheet of mixed targets and non-targets), DSST requires a relatively 
short (timed; often in the region of 2-3 minutes, although individual tasks vary) but 
intense period of concentration (during which the participant copies as many symbols as 
possible using a number key) and the continuous performance tasks normally involve 
monitoring changing stimuli for pre-specified targets over a prolonged period.
The term working memory was used to group tests that require very short-term retention 
of material for further processing. It was also used to cover short-term memory tasks 
such as immediate word and picture recall. Baddeley and Hitch (1974) first proposed 
the working memory system (and its three components: the central executive, the
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phonological loop, and the visuo-spatial sketchpad) as a flexible alternative to the 
unitary, limited capacity, short-term store proposed by earlier models such as Atkinson 
& Shiffiin’s (1971) multi-store model. No attempt was made here to distinguish 
between these theories, instead the term working memory was used to refer to tasks 
where the main element involved short term storage and some coding/processing of 
information followed relatively rapidly by retrieval or recall of that information. Several 
types of working memory task were identified and these were sub-divided based on the 
degree of manipulation of information required, and the modality in which the task was 
presented.
The long term memory category encompasses explicit, declarative memory tasks that 
require conscious recollection of previously learnt material. All the tasks identified in 
this review required free recall or recognition of words, prose or pictures following a 
delay after the initial learning period. The delay between learning and recall varied 
considerably between studies, from approximately 10 minutes to over 3 hours.
Executive function involves co-ordination of complex processes such as speech, motor 
co-ordination, and behavioral planning (Bennett, 2006). Impairments in executive 
function can result in impulsive behaviour; lack of cognitive flexibility; inability to plan 
ahead; and poor reasoning, problem solving and rule acquisition. Executive function 
covers a broad range of functions and the large number and variety of tasks assigned to 
this category reflects this. The sub-divisions made were reasoning, time estimation, 
fluency (i.e. ability to generate items from a given category), complex calculation, 
decision making, and ‘other’ (which included cognitive flexibility and critical flicker 
fusion (CFF)). There is some debate as to what function CFF actually indexes. The task 
itself is widely used in psychopharmacology research (along with DSST and choice
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reaction time it was one of the most frequently observed tests in this review) and 
involves the participant discriminating ‘flicker’ from ‘fusion’ and vice versa in a 
flickering light, where the frequency of flickering is gradually increasing or decreasing. 
Curran (1990) suggests that CFF assesses the ‘integrative capacity of the central 
nervous system to process discrete ‘bits’ of information’, or information processing, and 
on this basis it was included in the executive function category.
Tasks which assess motor performance are concerned with co-ordination and speed of 
performance. Motor performance involves motor learning and motor control and the 
tasks used to assess it require movement and precision/accuracy, gross or fine motor 
skill, discrete or continuous performance, and the task demands can vary according to 
whether the environment is fixed or changing. The motor tasks identified in this review 
were subdivided into the following categories: tracking & hand-eye co-ordination; 
driving tasks; dexterity; and psychomotor speed.
Reaction time is an indicator of sensorimotor performance and refers to speed of 
response. Typically, reaction time tasks measure two types of reaction time -  
recognition reaction time and motor reaction time. Recognition reaction time refers to 
the ‘cognitive’ processes involved (i.e. registering the stimuli) and motor reaction time 
refers to the movement component (i.e. the time taken to physically respond to the 
presence of the stimuli). The reaction time tasks identified in this review were 
separated into simple, complex and choice reaction time. Simply, the difference 
between these depends on the number of stimuli the participant was required to attend to 
and the number of responses they were required to make.
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Due to low numbers of observations no analysis of the cognitive or psychomotor test 
sub-categories was undertaken. However, it is worth bearing these sub-categories, and 
the potential differences between them, in mind when interpreting the results by 
function.
2.3.2 Percentage impairments
Table 3 summarises the number of cognitive and psychomotor impairments and no 
impairments detected with each drug. Dividing the drugs by class, it is evident that a 
greater percentage of impairments relative to no impairments was observed with the 
TCAs than any of the other drug classes (49.8%). This finding is in agreement with the 
view that although there is little difference with relation to efficacy, the TCAs are 
generally more associated with side effects and impaired cognitive abilities than the 
SSRIs, or MAOIs, for instance (Hindmarch, 1999). The NERIs (0%), RIMAs (5.7%), 
and SNRIs (6.2%) appear to be associated with a lower percentage of impairments to no 
impairments than either the TCAs (49.8%) or the SSRIs (14.5%). However, this m aybe 
an artefact, particularly in terms of the NERIs and SNRIs, due to the smaller number of 
studies with these drug classes included in this review. The group of compounds known 
as atypical antidepressants appear to have a relatively high percentage of impairments 
relative to no impairments (33.3%). However, this group of drugs is much more 
heterogeneous than the others and their modes of action, while unlike drugs from other 
classes, may be rather different from each other. This relatively high percentage of 
impairments may not, therefore, reflect accurately on all drugs from this class so the 
result should be interpreted with caution.
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2.3.3 PIR analysis
The PIR calculations for each drug included in this review, irrespective of dose, 
regimen, or test category, are presented in Table 4. The greater the PIR value the greater 
is the impairment associated with the use of a particular antidepressant. Values of, or 
close to, zero indicate no evidence of impairment. A drug which selectively disrupts 
performance (e.g. where a drug has impairing effects at higher doses only, or where 
impairment is limited to a particular facet of performance) will have a PIR value closer 
to zero than a drug which is impairing across the board.
Table 4 demonstrates that amitriptyline is by far the most impairing of all the 
antidepressants reviewed with a PIR value of 3.14. This is as expected, since many 
antidepressant trials, including some of those included in this review, use amitriptyline 
as a vertim due to its known impairment potential (Sherwood & Hindmarch, 1993). 
Mianserin closely followed with a PIR of 2.63. Like amitriptyline, mianserin is known 
to exert negative effects on performance (e.g. Hindmarch, 1997; Hindmarch & Kerr, 
1992) so this finding also supports previous research.
Mirtazepine (PIR=1.83), trazodone (PIR=1.50), nefazodone (PIR=1.46), doxepin 
(PIR=1.37), zimelidine (PIR=1.29), imipramine (PIR=1.20), sertraline (PIR=1.13) and 
dothiepin (PIR=1.05) all had PIRs greater than one indicating that these drugs were also 
associated with impairments in performance. It is unsurprising that the TCAs doxepin, 
imipramine and dothiepin appear in this list, indeed, like amitriptyline, these drugs are 
sometimes used as positive controls due to their known impairing effects. Perhaps more 
noteworthy is the observation that the three atypical antidepressants mirtazepine, 
trazodone and nefazodone all have relatively high PIRs. As mentioned previously it is 
difficult to draw conclusions about the atypical antidepressants as a group owing to the
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heterogeneous nature of the class, although previous work has noted that trazodone can 
cause sedation (e.g. Amado-Boccara et al., 1995) and the BNF cautions that mirtazepine 
may cause sedation. Thus, it is possible that impairments in performance with these two 
drugs are mediated through sedative effects. More surprising is the appearance of the 
SSRI sertraline in this list of relatively impairing drugs. It is interesting therefore that in 
a review of SSRIs Kasper & Heiden (1995) noted that the molecular structures of drugs 
within this class differ from each other, and that sertraline (and paroxetine -  to be 
discussed shortly) in particular, have effects at cholinergic muscarinic receptor sites. 
Along with their antihistaminic action, it is the anticholinergic properties of TCAs 
which lead to their side effects, much like those seen with sertraline in this analysis.
Maprotiline (PIR=0.98), citalopram (PIR=0.49), moclobemide (PIR=0.39), paroxetine 
(PIR=0.38), venlafaxine (PIR=0.28), fluoxetine (PIR=0.14) and lofepramine (PIR=0.10) 
were also all related to some degree of impairment in the main PIR analysis. As a 
tetracyclic this could be expected of maprotiline. Impairment is generally more unusual 
in the SSRIs, and this is home out by the lower PIR values for these drugs. Some degree 
of impairment with paroxetine would be expected given its anticholinergic effects. The 
SNRI venlafaxine and the SSRI fluoxetine show some slight impairments, although the 
PIR values are relatively low.
The list of drugs for which a PIR value of zero was observed (indicating no impairment 
relative to all the other drugs reviewed) consists of the atypical agents minaprine, 
nomifensine and tianeptine; the RIMAs befloxatone, brofaromine, RS-8359 and 
toloxatone; the SSRIs clovoxamine and escitalopram; the SNRI milnacipran; the NERIs 
reboxetine and binedaline; and the TCA desipramine.
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From the data presented in Table 4 it appears that as a class the RIMAs, NERIs and 
SNRIs tend to be associated with fewest impairments in performance, and the TCAs 
with most. Table 5 presents the combined PIR values for each of the drug classes which 
demonstrates the differences between the classes more clearly. It does also show, 
however, that there were fewest studies available for review with the SNRIs and NERIs.
In order to examine the drug data in relation to the measures used. Table 6 presents a 
summary of impairments and no impairments along with PIRs by test category, and 
Tables 7 to 12 break that information down further by drug class.
Overall, the functions indexed by each of the test categories were impaired to some 
degree, although according to percentage impairment relative to no impairment 
measures of motor performance (87% impairment) were affected most. In terms of 
PIRs, measures of divided attention (PIR=1.27) were most impaired, closely followed 
by motor performance (1.08), executive function (1.07) and reaction time (PIR=1.06). 
Working memory appeared to remain most intact according to both measures (24% 
impairment, PIR=0.80). However, it is likely that these figures are artificially inflated 
due to the fact that certain tests are used with more frequency than others in clinical 
drug trials, and also that there are inter-drug differences with regard to the functions 
affected. When interpreting these results it is also important to bear in mind that 
although it is important to use a variety of measures in order to assess all aspects of 
performance certain tests may be more sensitive to the effects of psychotropic 
medications than others.
Tables 7 through 12 show that, overall, measures of divided attention and long term 
memory were used relatively infrequently. Tests of motor performance were also used
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infrequently with drugs of the RIMA class, and sustained attention measures were 
infrequent with the NERIs. It seems unlikely this is a selective bias intended to neglect 
particular ‘problem areas’ with these drug classes. In both cases, but particularly with 
the NERIs, there was generally a low number of observations which may explain the 
effect. The total number of observations for the SNRIs was 16 and the number of 
observations for the NERIs was 39 (out of a total of 754, and contrasted with RIMAs = 
88, atypical = 123, SSRIs = 197 and TCAs = 291). These differences are most likely 
attributable to the fact that the TCAs and SSRIs are the most frequently used and 
therefore the most frequently researched. In addition, as discussed previously, the TCAs 
are often used as control drugs because of their known impairing effects on 
performance.
In terms of drug class specific impairments in function, among the TCAs while most 
measures were well represented (with the exception of low numbers of observations for 
divided attention and long term memory as discussed above) divided attention (62.5%, 
PIR=1.25) and executive function (56.9%, PIR=1.18) were the most impaired. As there 
were only 8 observations for measures of divided attention it is possible that this effect 
is unreliable. Motor performance (56.1%, PIR=1.16) and reaction time (54%, PIR=1.09) 
were impaired to almost the same degree as executive function. Working memory and 
sustained attention were the least impaired but even so the respective percent 
impairments and PIRs were 38.3%/PIR=0.73 and 37.2%/PIR=0.71, indicating a 
moderate amount of impairment. Returning to table 3, within the TCA drug class 
amitriptyline and mianserin accounted for 186 observations out of total of 291 for the 
drug class as a whole. The large number of observations and large numbers of 
impairments with these drugs across a wide variety of tasks illustrates the reason why 
they are so often used as positive controls.
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With regard to the SSRIs as a class most cognitive and psychomotor fonctions were 
well represented (again, with the exception of divided attention and long term memory), 
with the greatest number of impairments being in divided attention (33.3%, PIR=2.44) 
and sustained attention (27.8%, PIR=2.36), followed by reaction time (22.9%, 
PIR=1.90). Executive fonction (9.5%, 0.63), working memory (6.7%, PIR=0.44) and 
motor performance (8.2%, PIR=0.37) were least affected. On inspecting the number of 
impairments and no impairments by individual antidepressant (see Table 3), it can be 
seen that sertraline, followed by citalopram, paroxetine and zimelidine accounted for a 
large proportion of the impairments observed. This coupled with the suggestion of 
Kasper & Heiden, discussed previously, that there may be molecular differences 
between the SSRIs, raises the possibility that there may be a split between those which 
exert anticholinergic effects (e.g. sertraline, paroxetine) and those which do not. The 
results observed here would suggest that sertraline, paroxetine, citalopram and 
zimelidine are more prone to impairing performance than the SSRIs clovoxamine, 
escitalopram, fluoxetine and fluvoxamine.
There was a reasonable number of observations for the RIMAs overall, although tests of 
divided attention and motor control were not well represented. Motor performance was 
most impaired according to the PIR value (PIR=2.19), although the percentage 
impairment was low (11.1%) and this was based on only 9 observations in total. 
Sustained attention had the second highest PIR value (PIR=1.44) but again the 
percentage impairment was low (7.7%). No impairment at all was detected in tests of 
divided attention or long term memory (%0 impairment and PIR=0 for both) although in 
the case of divided attention this was based on just one observation.
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There were relatively low numbers of observations for the NERIs and SNRIs. Even so, 
between the two classes only one impairment was observed (in executive function with 
the SNRI venlafaxine). All PIRs were zero, and the only percentage impairment above 
zero was 25% impairment on executive function with the SNRIs (the one impairment 
with venlafaxine). There were only four drugs in total from these two drug classes, 
although the lack of impairment with reboxetine is notable - there were 32 observations 
and no impairments with this drug.
The largest number of impairments observed within the atypical class was in tests of 
long term memory (60%, PIR=1.86) and working memory (40%, PIR=1.25). Reaction 
time (27.8%, PIR=0.81) and sustained attention (26.3%, PIR=0.76) were least impaired, 
although the percent impairments and PIRs are still quite high -  like the TCAs there is 
not much variation between the impairment score in the most affected and least affected 
domains, suggesting a moderate but general impairment of function with both of these 
drug classes. Going back to Table 3, and a point made previously about the dangers of 
assuming that the atypical antidepressants are all similar to each other because they 
share the same drug ‘class’ (this in itself is a misnomer as the label atypical 
antidepressants describes less a class of drugs and more an umbrella term for a group of 
drugs which do not fit neatly into any of the more well-defined classes), there appears to 
be a split between drugs which seem to be impairing and drugs which do not. There is 
not one observed impairment with minaprine, nomifensine or tianeptine (although again 
the problem of fewer observations with these drugs is present), but approximately equal 
numbers of impairments and no impairments with mirtazepine, nefazodone and 
trazodone.
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2.3.4 ES estimates
PIRs can give an indication of the ratio of impairment of a particular drug compared to 
no impairments or other drugs, or a ratio of impairment detected by a particular test or 
group of tests compared to other tests. In effect, the PIR indexes the frequency of 
impairment. However, the average ‘amount’ of impairment cannot be captured by this 
method. In order to address this ES estimates were calculated.
17 studies were identified from which Cohen’s d could be calculated. In the majority of 
papers reporting studies included in this review descriptive statistics, results of 
statistical analysis (the most common being F  values from repeated measures ANOVA 
or t values from related samples t-tests) and p- values were only reported where findings 
were significant. 18 studies reported p-values only or no statistics at all.
Table 13 presents a summary of the mean ES estimates where a significant impairment 
or improvement was found, for each drug. Of the original 31 drugs, it was possible to 
compute effect sizes for 13 drugs. 11 of these drugs caused impairment in some aspect 
of performance in at least one of the studies included in the review. Table 13 
demonstrates that of these 11 drugs the TCAs dothiepin (mean d=-2.43), mianserin 
(mean d=-2.28) and amitriptyline (mean d=-1.70) and the atypical antidepressants 
mirtazepine (mean d=-1.33) and trazodone (mean d=-1.16) all had ES estimates of 
impairment greater than one (where a negative ES represents an impairment in 
performance and a positive ES represents an improvement in performance) and none of 
these drugs was associated with any improvement in performance. It is interesting that 
the three drugs which were associated with the highest frequency of impairment (as 
indicated by the PIRs) also have the largest magnitudes of effect (although the ES data
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is confounded somewhat by the inclusion only of significant findings, which to some 
extent exaggerates the relationship between the PIR and ES).
There is no agreed standard for interpretation of ES. Cohen (1977) suggested that in the 
absence of other standards d=0.2 could be considered a small effect size, d=0.5 a 
medium effect and d=0.8 a large effect. Wolf (1986) advised interpreting effect sizes in 
relation to other research within the field. This review makes interpretation of ES easier 
by allowing the comparison of multiple ESs across different drugs which provides a 
type of standard for comparison. Using a comparison across drugs in combination with 
Cohen’s approximations it seems that the effect sizes for the 11 antidepressants which 
were associated with impairment range from low (fluvoxamine d=-0.27, citalopram d=- 
0.29) to very high (dothiepin d=-2.43). ES estimates in the direction of improvement 
were found with 5 drugs: nefazodone (d=6.51), paroxetine (d=2.05), moclobemide 
(d=0.89), sertraline (d=0.33) and citalopram (d=0.20). Nefazodone and paroxetine in 
particular seem to be associated with large improvements in performance. In terms of 
nefazodone, this effect may be explained by its unique pharmacology (in addition to its 
serotonin and noradrenaline reuptake blocking properties, it is also a 5 -HT2 antagonist -  
this is thought to be responsible for the anxiolytic effects observed with nefazodone). 
Paroxetine was also associated with an intermediate sized ES (d=-0.89) indicating a 
decrement in performance. This indicates some conflict in the data. The ES estimate 
was computed using data from 5 different studies, using data from 8 separate 
psychometric tests half of which were impaired following paroxetine and half of which 
were improved. The ES estimates suggest that where improvements were observed 
with paroxetine the effect was larger than where impairments with paroxetine were 
observed. These paradoxical effects may be dose dependent, or related to dosing 
regimen. Moclobemide had low to medium ES estimates for both improvements
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(d=0.89) and impairments (d=-0.32) in performance. These suggest that the magnitude 
of impairments seen with moclobemide is smaller than the magnitude of improvements. 
Citalopram had low ES estimates for both impairments (d=-0.29) and improvements 
(d=0.20). As these estimates are low it is possible that the conflict could be due to inter­
individual differences in response to the drug, divergent effects according to the 
function being measured, differences in effect according to drug dose, or varying 
sensitivity (or procedures) in the tasks used across the different studies.
Figure 2 presents impairment and improvement ES estimates for the individual drugs 
graphically.
Table 14 compares the impairment and improvement effect sizes across the three drug 
classes for which data was available: the TCAs, SSRIs and atypical antidepressants. 
Overall, the TCAs unequivocally impaired performance with an ES of d=-1.45. The 
atypical antidepressants impaired performance with an effect size equivalent to that of 
the TCAs (d=-1.46) but also improved performance to a large degree (d=3.70). This 
provides further evidence that the atypical antidepressants are a heterogeneous group in 
terms of the effects they exert on cognitive and psychomotor performance. The SSRIs 
moderately impaired performance (d=-0.66), but improved it to a larger extent (d=l .45). 
This may also, in part, be due to differences among the drugs belonging to this class.
Table 15 provides a summary of impairment and improvement ES estimates for each 
cognitive or psychomotor function; that is the extent to which tests of each function are 
impaired by antidepressant drugs. It could be argued that these estimates provide a 
measure of which functions are affected by the administration of antidepressant 
medication. The counter-argument is that this provides a measure of the sensitivity of
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the tasks to detect changes in performance brought about by antidepressant drugs. 
Figure 3 presents the same information graphically. These effect sizes show that 
following antidepressant treatment divided attention (d=-2.01), executive function (d=- 
1.72), motor performance (d=-1.37), working memory (d=-1.32), and reaction time (d=- 
1.22) are all highly impaired. Medium to large sized impairments are seen in sustained 
attention (d=-0.88) and small impairments are seen in tests of long term memory (d=- 
0.34). These ES estimates indicate that antidepressant medication administered to 
healthy volunteers is impairing across a broad range of cognitive and psychomotor 
functions. However, enhanced performance is also seen following antidepressant 
medication in sustained attention (d=3.51), reaction time (d=1.60) and executive 
function (d=1.47).
Table 16 presents more detailed data regarding impairment and improvement ES 
estimates in each test category by drug class. This reveals that all cognitive and 
psychomotor functions were highly impaired by the TCAs (d=-0.94 to -3.53). The only 
exception to this was long term memory for which an ES could not be calculated. The 
most pronounced impairments with the TCAs were in tasks of divided attention. There 
were no improvements in performance following treatment with TCAs.
There was no impairment in executive function or sustained attention following 
treatment with SSRIs. The other test categories were all impaired a low to 
moderate/high amount (d=-0.34 to -1.12). Reaction time was improved (d=2.31) to a 
greater extent than it was impaired (d=-0.49). Executive function was highly improved 
following SSRI treatment (d=1.47) and sustained attention was moderately improved 
(d=0.51).
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No data was available relating to impairments or improvements in long term memory 
following treatment with atypical antidepressants. Motor performance (d=-2.19), 
divided attention (d=-1.99), executive function (d=-1.49) and reaction time (d=-1.44) 
were highly impaired by the atypical antidepressants. Sustained attention was 
moderately impaired (d=-0.55) and working memory was marginally impaired (d=- 
0.13). Despite also being impaired, reaction time with atypical antidepressants was 
moderately improved (d=0.89). Sustained attention was greatly improved (d=6.51) 
despite also being moderately impaired. This improvement in sustained attention seems 
mostly to be due to the effects of nefazodone.
In summary, the ES estimates show great variation both among drugs/drug classes and 
among cognitive and psychomotor test functions. This variability underlines the 
importance of (a) comprehensively testing drugs for effects on a wide range of 
performance measures, before targeting the effects believed to be likely based on the 
chemistry or profile of the drug, and (b) taking care to interpret null findings in the 
context of the functions being measured.
2.4 Conclusions
In summary, there are differences both among and between antidepressant drug classes 
in their potential to cause disruption to cognitive function and psychomotor 
performance. On the whole the TCAs and the atypical antidepressants appear to be 
associated with the most frequent impairments in performance (although there are some 
exceptions to this which have been discussed) and in addition, where impairments were 
noted, these drugs were also associated with the largest magnitude of effects. Of the 
newer classes of antidepressant, the SSRIs were associated with medium-frequency of 
impairments in performance coupled with low to moderate effect sizes. The RIMAs and
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NERIs appeared to be the least impairing of all the drugs reviewed in terms of 
frequency of decrements. It was not possible however to assess the magnitude of 
impairments for these drug classes. Within each of the drug classes there were 
differences between antidepressants.
In terms of the cognitive and psychomotor tasks, overall the greatest frequency of 
impairments was observed with tasks assessing motor performance, and the largest 
magnitude of effects was associated with measures of divided attention. Different drugs 
and drug classes appeared to impair different cognitive and psychomotor functions to 
different extents. No one function appeared to be particularly sensitive across all drugs 
and classes, and this likely reflects the different actions of these drugs.
In addition, some improvements in performance were observed with some drugs and it 
is possible that these effects could, depending on the needs of the individual patient, be 
used therapeutically.
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3. GENERAL DISCUSSION & CONCLUSIONS
3.1 Summary of findings
The findings of this review reveal a general pattern of impairments caused by different 
antidepressant drug classes - the TCAs and atypical antidepressants tend to be 
associated most often with impairments in performance, the SSRIs are associated with a 
medium frequency of impairment and the RIMAs with low frequency of impairment. 
SNRIs and NERIs are also associated with low levels of impairment, although these 
have not been subject to as much research as the other drug classes, so it is difficult to 
draw conclusions about them. This review also highlights that there are differences both 
between and within drug classes in terms of the overall amount of impairment observed, 
and in terms of the amount of impairment observed across different functions. The 
TCAs seem to be most associated with impairments in complex (executive) function, 
motor performance and reaction time, indicating general impairment across cognitive 
and motor functions. The SSRIs seem to most affect sustained attention and reaction 
time; atypical antidepressants appear to most affect working memory and long term 
memory; the RIMAs cause little impairment in all functions assessed; and the SNRIs 
and NERIs also cause very little impairment (although, again, it is hard to draw 
conclusions about these due to the limited number of studies available). In terms of the 
magnitude of effects observed, in addition to being associated with a high frequency of 
impairment the TCAs are also associated with treatment effects of large magnitude. 
While the atypical antidepressants are associated with large effect sizes in the direction 
of impairment they also produce some improvement, and the SSRIs produce relatively 
low effect sizes in the direction of impairment but also moderate improvements. In 
terms of the functions assessed, divided attention, motor control, and working memory 
tasks were associated with moderate to large effect sizes in the direction of impairment.
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while long term memory was associated with a small negative effect size. Measures of 
executive function, reaction time, and sustained attention also demonstrated fairly high 
magnitudes of improvement. There are two alternative explanations for these 
differences across function. It could be that certain tasks are more affected by 
antidepressant drugs (possibly reflecting the mechanism of action of these drugs) or it 
may be that certain types of task are more sensitive to capturing improvements in 
performance as well as impairments. The potential to both improve and impair 
performance should be considered when making prescribing decisions.
3.2 Inclusion / exclusion criteria
The inclusion criteria of this review required each study to include a comparator drug, 
or positive internal control. This was to maintain consistency across the trials being 
compared. A further requirement was that the comparator drug was also an 
antidepressant. Again, this was for purposes of consistency. The inclusion of non­
comparator studies or studies with comparators from different drug classes may have 
increased the number of studies of SNRIs and NERIs which would have been beneficial 
in this instance. However, comparators provide a measure of the sensitivity of the tasks 
used, and the large amount of impairments with the traditional comparator drugs (e,g, 
amitriptyline, mianserin) in this review suggest that the inclusion of positive controls is 
effective, and therefore an important part of the methodology.
It was also a requirement of this review that the studies included reported the effects of 
antidepressant treatment upon objective assessments of performance. Studies where 
only subjective assessments were used were excluded, and similarly, where a study 
employed both objective and subjective measures only the objective measures were 
included in the review. It is possible that subjective measures (e.g. mood questionnaires
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or rating scales) may provide additional information more related to the individuals’ 
experience. However, this would be more valuable in patient groups, and therefore if a 
similar review was to be conducted but focused on depressed patients rather than 
healthy volunteers, this should include subjective as well as objective measures.
3.3 Methodological issues
Several issues related to the design of the studies included in the review complicate 
interpretation of the pooled data.
One major distinction between the studies is the use of acute vs. repeated dosing 
regimens. Obviously, repeated dosing better reflects the clinical use of antidepressants. 
Acute dosing runs the risk of failing to detect changes in performance related to either 
sensitization or tolerance. Many studies employing repeated dosing also test for acute 
effects (e.g. after 1®^ dose), so the impairment counts for repeated dosing do not 
necessarily reflect a longer length of dosing in all cases.
In this review differences in actual doses used across studies were also apparent. 
Amitriptyline for example, was used in doses of between 25 to lOOmg. The BNF 
recommends a starting dose of 75mg, so it is possible that in some studies the 
impairment potential of amitriptyline has been underestimated. Table 17 shows the dose 
ranges used in the studies reviewed compared with the BNF recommendations for these 
drugs (note that the BNF does not recommend all of the drugs reviewed, as not all are 
available in the UK). The table demonstrates that generally speaking the studies cover a 
good range of recommended initial doses in clinical practice, although some of the 
higher end recommended doses are not represented. Potentially this could mean that 
effects at high doses have been masked.
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In addition to issues with dosing, there are also wide differences between studies in 
terms of the assessment of performance, both in the type and number of tasks used, and 
in the assessment schedule employed. Some studies use a ‘blanket approach’ with many 
tests and frequent time points, while others target specific aspects of function at 
particular ‘risk’ times (e.g. time of peak drug effect or plasma level). The likelihood of 
Type I errors is increased where there are multiple tasks and multiple time points.
A particular problem that was encountered in calculating ES estimates was inadequate 
reporting of non-significant findings. This is related to the general publication bias for 
positive findings. However, to allow pooling of data with meta-analytic techniques it is 
crucial that papers fully report both significant and non-significant findings. In this 
review only 17 of 62 papers reported enough detail for cohen’s d estimates to be 
calculated, and even then not all of these gave adequate detail regarding non-significant 
findings.
3.4 Meta-analvtic methods
The PIR technique is a useful way to compare the frequency of impairments across 
different drugs. However, there are certain limitations that should be noted. The PIR 
method does not take account of the number of instances of impairment with the same 
drug in a particular study. For example, study 35 (Kerr et al., 1992) contrasted 
moclobemide and amitriptyline, and both drugs were rated as impairing short term 
memory scanning performance. Closer inspection of the findings, however, reveal that 
while moclobemide impaired performance on this task at only one time point, 
amitriptyline impaired performance on this task at 9 separate time points. In terms of the
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PIR method no discrimination between the two drugs was made. In part, the ES 
estimates were calculated to address this issue.
On a related note, where both impairments and no effects were observed with the same 
task in a single study (i.e. if  multiple time points were used) the PIR method listed the 
task as ‘impaired’. Not factoring in instances of ‘no effect’ could provide a skewed 
picture. If it happens consistently, it has the potential to inflate estimates of the 
frequency of impairment. That said, it is possible that where multiple time points are 
used in a single study some of those time points could occur after the drug has worn off, 
for example. Therefore if  the number of instances of no effect were taken into account it 
would be important to also consider times of peak drug effect and the elimination half- 
life of the drugs concerned. It is also important to note the possibility that observations 
of no effect could be artificially increased where the psychometric measures used are 
not sensitive enough to pick up any impairment.
Further limitations of the PIR technique are that it does not provide any statistical test of 
confidence, it gives no weighting to studies of different sizes, and no account is taken of 
the number of time points or number of different response measures in a study. ES 
estimates go some way towards addressing these concerns.
3.5 Test categorisation
In terms of interpreting the effects observed by test category, it is important to note that 
while every care was taken to separate the tasks into groups so that tasks reflecting 
similar functions were grouped together, given that seven fairly broad categories were 
used it is possible that each category is quite heterogeneous. Where certain tests are 
used with more frequency (for example, digit symbol substitution, critical flicker fusion
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and choice reaction time were all observed very frequently in this review compared to 
other tasks) this could bias the entire category, particularly where a large number of 
impairments, for example, are observed.
3.6 Clinical significance
PIR and ES estimates can be useful tools to assist in making comparisons between 
drugs, however they do not indicate whether the effects observed are clinically 
significant (i.e. whether the extent of any changes in performance will impact ‘real- 
world’ activities). Clinical significance should be considered on an individual basis, in 
conjunction with the needs of the individual patient.
3.7 Special populations
This review did not consider the effects of factors such as age or gender on drug-related 
impairments. Some of the studies included used exclusively male or elderly populations, 
for example. However, no separate analyses were performed on these groups. It is likely 
that any such interactions would be more pronounced in patient groups, and should 
therefore be investigated in depressed patients. In depressed elderly patients 
particularly, caution is advised when prescribing antidepressants. Concomitant drug 
therapy and/or disease, poor compliance, and age-related changes in pharmacokinetics, 
drug sensitivity and cognition can make older patients especially vulnerable to the 
adverse effects of medication (Norman, 1993).
3.8 Summary & future research directions
Many factors, other than efficacy, influence drug choice and therapeutic usefulness. 
These include the potential of a drug for adverse effects, and, it is in this context that the 
present review has been carried out on the potential of antidepressants to impair
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cognition and psychomotor performance. The methodology of meta-analysis has been 
used in an attempt to quantify the differences that exist between antidepressants and so 
indicate their relative potential to impair or improve the quality of life for individuals 
with depression.
Contrary to expectation the use of meta-analysis has not allowed conclusions to be 
drawn on the relative significance to the patient or to the clinician of the various adverse 
effects of antidepressants on cognition and psychomotor performance. The limitations 
of the meta-analysis are related to the inadequacy of the data with the inherent 
heterogeneity of the activity of the drugs, the lack of similar data on various skills 
between studies, and different experimental designs. The available data indicate that 
there are differences both between and within antidepressant drug classes, but do not 
permit a useful comparative analysis. Clinical efficacy may not have been established 
between drugs that are being compared, drugs may be compared without adequate 
consideration of dose and time from ingestion, and tasks that are believed to index 
functions of particular significance, such as divided attention and memory, are often not 
included in the test batteries.
Essentially, this review has indicated the methodology that would be required if  meta­
analysis was to be used as a potential approach to quantifying the relative adverse 
effects of drugs on cognition and psychomotor function. In this context much more 
emphasis needs to be given to sample sizes and power calculations of the studies being 
compared, and data are needed on studies that have failed to demonstrate efficacy but 
have shown impairments in performance. This review has also emphasized the need for 
analysis of sub-groups, particularly related to age, if  useful clinical data is to be 
forthcoming. Consideration must also be given to comparative analyses of mood in
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studies dealing with such disorders, and the clinical usefulness of acute versus repeated 
dosing regimens in understanding the relationship between continued efficacy and 
tolerance must be explored.
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Table 6: Overall impairments and no impairments by test category
All drugs Impairments
No
impairments
%
impairment PIR
Divided attention 7 12 36.8% 1.27
Motor 52 116 87.4% 1.08
Exeeutive funetion 52 117 30.8% 1.07
Reaction time 41 93 30.6% 1.06
Long term memory 11 29 27.5% 0.94
Sustained attention 28.5 75.5 27.4% 0.93
Working memory 29 91 24.2% 0.80
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Table 7: Impairments and no impairments by test category -  TCAs
a b c d PIR
%
impairment
Divided attention 5 3 141 142 1.25 6Z5%&
Exeeutive
funetion
37 28 109 117 1.18 56.9%
Motor 37 29 109 116 1.16 56.1%
Reaction time 27 23 119 122 1.09 54%
Long term 
memory
6 6 140 139 1.00 50%
Working memory 18 29 128 116 0.73 38.3%
Sustained
attention
16 27 130 118 0.71 37.2%
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Table 8: Impairments and no impairments by test category -  SSRIs
a b c d PIR
%
impairment
Divided attention 1 2 27.5 166.5 2.44 33.3%
Sustained
attention
7.5 19.5 21 149 Z36 27.8%
Reaction time 8 27 20.5 141.5 1.90 22.9%
Long term 
memory
2 9 26.5 159.5 1.33 18.2%
Executive
function
4 38 24.5 130.5 0.63 9 J%
Working memory 2 28 26.5 140.5 0.44 6.7%
Motor 4 45 24.5 123.5 0.37 8.2%
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Table 9: Impairments and no impairments by test category -  RIM As
a b c d PIR
%
impairment
Motor 1 8 4 75 2.19 11.1%
Sustained
attention
1 12 4 71 1.44 7/M4
Working memory 1 15 4 68 1.13 6.25%
Exeeutive
function
1 17 4 66 0.97 5.6%
Reaction time 1 18 4 65 0.91 5.3%
Divided attention 0 1 5 82 0.00 0%
Long term 
memory
0 12 5 71 0.00 0%o
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Table 10: Impairments and no impairments by test category -  NERIs
a b c d PIR
%
impairment
Divided attention 0 2 0 37 0.00 0%
Exeeutive
funetion
0 12 0 27 0.00 0%
Long term 
memory
0 0 0 39 0.00 0%
Motor 0 8 0 31 0.00 0%
Reaction time 0 10 0 29 0.00 0%
Sustained
attention
0 1 0 38 0.00 0%
Working memory 0 6 0 33 0.00 0%
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Table 11: Impairments and no impairments by test category -  SNRIs
a b c d PIR
%
impairment
Divided attention 0 2 1 13 0.00 0%
Executive
function
1 3 0 12 0.00 25%
Long term 
memory
0 0 1 15 0.00 0%
Motor 0 6 1 9 0.00 0%
Reaction time 0 2 13 0.00 0%
Sustained
attention
0 1 1 14 0.00 0%
Working memory 0 1 1 14 0.00 0%
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Table 12: Impairments and no impairments by test category -  Atypical
a b c d PIR
%
impairment
Long term 
memory
3 2 38 80 1.86 60%
Working memory 8 12 33 70 1.25 40%
Divided attention 1 2 40 80 1.00 33.3%
Motor 10 20 31 62 1.00 33j%6
Executive
funetion
9 19 32 63 0.95 32.1%
Reaction time 5 13 36 69 0.81 27.8%
Sustained
attention
5 14 36 68 0.76 2&3%4
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Table 13: Summary of mean impairment and improvement ES estimates by drug
Drug Cohen’s d 
Impairment
Cohen’s d 
Improvement
Studies
Dothiepin -2.43 n/a 88
Mirtazepine -228 n/a 91,94
Mianserin -1.70 n/a 9,28,62
Amitriptyline -1.33 n/a 13,27, 28,35, 50, 63, 
86,87
Trazodone -1.16 n/a 28
Paroxetine -0.89 2.05 28,71,86,87,91
Moclobemide -0.52 0.89 4,35
Zimelidine -0.49 n/a 77
Doxepin -0.40 n/a 77
Citalopram -0.29 0.20 50,92
Fluvoxamine -0.27 n/a 9
Nefazodone n/a 6.51 87
Sertraline n/a 0.33 71
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Table 14: Mean impairment and improvement ES estimates by drug class
Drug class Cohen’s d 
Impairment
Cohen’s d 
Improvement
Cohen’s d 
Combined
Atypical -1.46 3.70 ±2.58
TCAs -1.45 n/a n/a
SSRIs -0.66 1.45 ±1.06
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Table 15: Impairment, improvement and combined ES estimates by function
Function Cohen’s d 
Impairment
Cohen’s d 
Improvement
Cohen’s d 
Combined
Studies
Divided
attention
-2.01 n/a n/a 86,94
Exeeutive
funetion
-1.72 ,1.47 ±1.60 9,13 ,27 ,28 ,35 , 
50, 62, 63,71,86, 
91
Motor control -1.37 n/a n/a 9 ,27 ,28 ,35 ,50 ,
86,88,94
Working
memory
-1.32 n/a n/a 35,86
Reaction time -1.22 1.60 ±1.41 4 ,9 ,13 ,27 ,28 ,35 , 
50, 62, 77, 91
Sustained
attention
-0.88 3.51 ±4.39 35, 50, 63, 87
Long term 
memory
-0.34 n/a n/a 71,92
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6. FIGURES
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Figure 1: Formula for calculation of PIR
a) Antidepressant PIR
a C
PIR =
a + b
divided by
c + d
Where:
a = number of impairments observed with a particular antidepressant 
b = number of no impairments observed with a particular antidepressant 
0 = number of impairments observed with all other antidepressants in the analysis 
d = number of no impairments observed with all other antidepressants in the analysis
b) Cognitive/psychomotor function PIR
a c
PIR =
a + b
divided by
c + d
Where:
a = number of impairments observed with a particular function/test type 
b = number of no impairments observed with a particular function/test type 
c = number of impairments observed with all other functions/test types 
d = number of no impairments observed with all other functions/test types
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